This reorganization placed nearly 2, research scientists into six centers of excellence in drug discovery CEDD. Each CEDD focused on a small set of therapeutic areas and possessed decision rights over the progression of pharmaceutical compounds through the early stages of development. It addresses issues about the benefits of focus vs. Merger leads to combined decision making for developments in pipeline, which leads to faster process of drug discovery. Economies of Learning: Alliances with smaller specialized firms, allows large firms to learn about new drugs and new technologies.
|Published (Last):||11 February 2010|
|PDF File Size:||19.89 Mb|
|ePub File Size:||12.98 Mb|
|Price:||Free* [*Free Regsitration Required]|
Benson, Robert J. Blendon, Robert S. Huckman and Sara J. Singer Context: The private sector has a large potential role in advancing health and well-being, but attention to corporate practices around health tends to focus on a narrow range of issues and on large businesses.
Systematically describing private sector engagement in health and well-being is a necessary step toward understanding the current state of the field and developing an agenda for businesses going forward. Methods: We conducted a national survey of 1, private sector organizations to assess current levels of engagement in what we term a culture of health CoH.
We measured corporate CoH along four dimensions, which assess the extent to which businesses promote employee, environmental, consumer, and community health and well-being. We also explored potential explanations for the number of health-related actions taken in each dimension. For each dimension, we found variation among businesses in the number of actions taken on average, there were almost fourfold differences between the bottom and top quartiles of businesses in terms of actions taken.
Fewer than half of businesses, however, perceived a positive return on their CoH investments. Conclusions: Overall, the private sector is taking steps to foster health and well-being. However, there remains substantial variation among businesses and opportunity for growth, even among those currently taking the most action. Strengthening the business case for a corporate CoH may increase private sector investments in health and well-being.
Actions taken by individual businesses, business groups, industries, and regulators have the potential to improve corporate engagement and impact.
GlaxoSmithKline: Reorganizing Drug Discovery (A)
Brushing up HBR fundamentals will provide a strong base for investigative reading. Often readers scan through the business case study without having a clear map in mind. This leads to unstructured learning process resulting in missed details and at worse wrong conclusions. Reading up the HBR fundamentals helps in sketching out business case study analysis and solution roadmap even before you start reading the case study. It also provides starting ideas as fundamentals often provide insight into some of the aspects that may not be covered in the business case study itself. Begin slowly - underline the details and sketch out the business case study description map. In some cases you will able to find the central problem in the beginning itself while in others it may be in the end in form of questions.
GlaxoSmithKline: Reorganizing Drug Discovery (A) Harvard Case Solution & Analysis
Case Report: Glaxosmithkline Reorganizing Drug Discovery (a)
GlaxoSmithKline: Reorganizing Drug Discovery (A) Case Study Analysis & Solution